51. Study of Common Genetic Variant S447X in Lipoprotein Lipase and Its Association with Lipids and Lipoproteins in Type 2 Diabetic Patients
- Author
-
Gouri M Bhoite, M. P. Bankar, and Abdulrahaman A. Momin
- Subjects
0301 basic medicine ,medicine.medical_specialty ,Lipoprotein lipase ,Very low-density lipoprotein ,Triglyceride ,Cholesterol ,business.industry ,Clinical Biochemistry ,Type 2 diabetes ,030204 cardiovascular system & hematology ,medicine.disease ,Genotype frequency ,03 medical and health sciences ,chemistry.chemical_compound ,030104 developmental biology ,0302 clinical medicine ,Endocrinology ,Insulin resistance ,chemistry ,Internal medicine ,medicine ,Original Article ,lipids (amino acids, peptides, and proteins) ,business ,Lipoprotein - Abstract
Elevated plasma triglyceride and non-esterified fatty acid concentrations may cause insulin resistance and type 2 diabetes mellitus. Lipoprotein lipase (LPL) is a rate-determining enzyme in lipid metabolism. A variant in the LPL gene has been identified which alters the penultimate amino acid Serine at 447 to a stop codon (S447X), and results in a truncated LPL molecule lacking the C-terminal dipeptide Ser–Gly. The present study was designed to evaluate the frequency of S447X variant in the LPL gene and its effect on the lipid and lipoprotein levels in type 2 diabetic subjects. The genotype frequency distributions of type 2 diabetes patients and controls were in Hardy–Weinberg equilibrium. Comparison of the genotype and allelic frequencies of S447X in subjects with type 2 diabetics compared to controls demonstrated no significant difference. In subjects with type 2 diabetics having hypertriglyceridemia (TG ≥ 150 mg/dl) compared to diabetics with TG level
- Published
- 2015
- Full Text
- View/download PDF